Compare Cassava Sciences Inc (FLNA) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while iShares Core MSCI Emerging Markets ETF trades at $78.11. The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | IEMG | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $86.00 |
52-Week Low | $1.09 | $59.90 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
The iShares Core MSCI Emerging Markets ETF (IEMG) trades at $78.08, down 2.06% on the day, with technical indicators showing a bearish bias. The fund has delivered strong recent performance, surging approximately 35% over the past year according to The Motley Fool (2026-06-24), driven by significant exposure to South Korean and Taiwanese technology stocks. Recent news highlights record inflows into emerging markets and IEMG's competitive 0.09% expense ratio compared to peers.
Outlook: IEMG offers concentrated, cost-effective exposure to high-growth emerging markets at a valuation discount to U.S. equities, but carries elevated volatility and geopolitical risks. Key opportunities include AI-driven tech exposure and strong dividend growth, while risks involve concentration in specific regions and sensitivity to U.S.-China tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
